Professor and Chair of Neurology
Neurology
Dr. David M. Holtzman, MD
|
|
Give Review
David Holtzman works in the field of Neurology. He researched medicine at Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine has a rank of 19 in research and a 29 in primary care He has 2 awards "CMS Meaningful Use Stage 1 Certification" and "Elected Member". David Holtzman is also a published doctor. He has 102 paper published. The most recent paper is: Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. Dr. David M. Holtzman accepts Medicare payments and is registered with Medicare.gov.
Publications
- TREM2 Function in Alzheimer's Disease and Neurodegeneration.
- Current thinking on the mechanistic basis of Alzheimer's and implications for drug development.
- Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
- microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain.
- A spectrum of exercise training reduces soluble Aβ in a dose-dependent manner in a mouse model of Alzheimer's Disease.
- Re-evaluation of the Blood-Brain Barrier in the Presence of Alzheimer's Disease Pathology.
- A potential endophenotype for Alzheimer's Disease: cerebrospinal fluid clusterin.
- TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer's Disease Model.
- Sigma-2 receptor binding is decreased in female, but not male, APP/PS1 mice.
- Anti-tau antibody reduces insoluble tau and decreases Brain atrophy.
- Apolipoprotein E levels and Alzheimer risk.
- Contribution of reactive oxygen species to Cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice.
- Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's Disease biomarkers.
- Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's Disease.
- The sleep-wake cycle and Alzheimer's Disease: what do we know?
- Anti-Aβ antibody target engagement: commentary regarding Watt et al. Acta Neuropathol 127:803-810 (2014).
- The Binding of Apolipoprotein E to Oligomers and Fibrils of Amyloid-β Alters the Kinetics of Amyloid Aggregation.
- Human Neurons Derived From Induced Pluripotent Stem Cells as a New Platform for Preclinical Drug Screening and Development.
- Cerebral amyloid angiopathy increases susceptibility to infarction after focal Cerebral ischemia in tg2576 mice.
- Functional connectivity in autosomal dominant and late-onset Alzheimer Disease.
- Effects of growth hormone-releasing hormone on sleep and Brain interstitial fluid amyloid-β in an APP transgenic mouse model.
- Apolipoprotein E mediation of neuro-inflammation in a murine model of Multiple sclerosis.
- The Ultrastructural Identity of Alzheimer's Pathology: Lessons from Animal Models.
- B-RAF unlocks axon regeneration.
- Progress Update: Fluid and Imaging Biomarkers in Alzheimer's Disease.
- Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease.
- Neuronal activity regulates extracellular tau in vivo.
- Missense variant in TREML2 protects against Alzheimer's Disease.
- Biomarker modeling of Alzheimer's Disease.
- Sleep and Alzheimer Disease pathology-a bidirectional relationship.
- Regional variability of imaging biomarkers in autosomal dominant Alzheimer's Disease.
- Functional connectivity and graph theory in preclinical Alzheimer's Disease.
- Relationship between Stroop performance and resting state functional connectivity in cognitively Normal older adults.
- Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo.
- The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-ε4 Carriers.
- Sleep evaluation by actigraphy for patients with Alzheimer Disease-reply.
- Cerebrospinal Fluid Aβ42, Phosphorylated Tau181, and Resting-State Functional Connectivity.
- Antisense Reduction of Tau in Adult Mice Protects against Seizures.
- Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later.
- Sleep quality and preclinical Alzheimer Disease.
- ApoE influences amyloid-? (A?) clearance despite minimal apoE/A? association in physiological conditions.
- GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease.
- Blocking the Interaction between Apolipoprotein E and A? Reduces Intraneuronal Accumulation of A? and Inhibits Synaptic Degeneration.
- SOD1 in Cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.
- Amyloid-beta oligomerization in Alzheimer Dementia versus high-pathology controls.
- Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice.
- Toward a multifactorial model of Alzheimer Disease.
- Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.
- 11C-PiB Imaging of Human Immunodeficiency Virus-Associated Neurocognitive Disorder.
- Mapping the road forward in Alzheimer's Disease.
- Neuroprotective role of Sirt1 in mammalian models of Huntington's Disease through activation of multiple Sirt1 targets.
- Cerebrospinal Fluid Proteins Predict Longitudinal Hippocampal Degeneration in Early-stage Dementia of the Alzheimer Type.
- Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-? Amyloidosis.
- CSF biomarkers for Alzheimer's Disease: current utility and potential future use.
- Tau elevations in the Brain extracellular space correlate with reduced amyloid-? levels and predict adverse clinical outcomes after severe traumatic Brain injury.
- Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitoToxic-necrotic cell death.
- Dynamic Analysis of Amyloid ?-Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal A? during Age-Related Plaque Formation.
- The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on A? induced membrane disruption.
- In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice.
- Cerebrospinal fluid biomarkers, education, Brain volume, and future cognition.
- Opposing Synaptic Regulation of Amyloid-{beta} Metabolism by NMDA Receptors In Vivo.
- Visinin-like protein-1: Diagnostic and prognostic biomarker in Alzheimer Disease.
- The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.
- Human apoE isoforms differentially regulate Brain amyloid-β peptide clearance.
- Controlled Cortical Impact Traumatic Brain Injury in 3xTg-AD Mice Causes Acute Intra-Axonal Amyloid-{beta} Accumulation and Independently Accelerates the Development o...
- Alternative processing of ?-secretase substrates in common forms of mild cognitive impairment and alzheimer's Disease: Evidence for ?-secretase dysfunction.
- Neuronal activity regulates the regional vulnerability to amyloid-β deposition.
- Critical Role of Astroglial Apolipoprotein E and Liver X Receptor-{alpha} Expression for Microglial A{beta} Phagocytosis.
- Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of {beta}-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pa...
- Alzheimer Disease: advances in pathogenesis, diagnosis, and therapy.
- The diagnosis of mild cognitive impairment due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagn...
- Alzheimer's Disease: the challenge of the second century.
- Diffusion characteristics associated with neuronal injury and glial activation following hypoxia-ischemia in the immature Brain.
- Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice.
- Reply to: Fractional synthesis and clearance rates for amyloid ?.
- Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's Disease.
- Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis.
- Traumatic Brain injury reduces soluble extracellular amyloid-β in mice: a methodologically novel combined microdialysis-controlled cortical impact study.
- YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's Disease.
- Medicine. Prion-like behavior of amyloid-beta.
- Are CSF biomarkers ready for prime time as diagnostics for Alzheimer Disease? Interview by Rebecca Voelker.
- Exercise and Alzheimer's Disease biomarkers in cognitively normal older adults.
- SIRT1 promotes the central adaptive response to diet restriction through activation of the dorsomedial and lateral nuclei of the hypothalamus.
- Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's Disease.
- Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's Disease.
- Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex.
- APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively Normal aging.
- Overexpression of low-density lipoprotein receptor in the Brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.
- Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realization.
- Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer Disease: a case...
- Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer Disease.
- Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle.
- The utility of intraindividual variability in selective attention tasks as an early marker for Alzheimer's Disease.
- Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer's Disease.
- Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice.
- Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in Cerebral amyloidoses.
- The role of apolipoprotein E in Alzheimer's Disease.
- Biomarkers of Alzheimer's Disease.
- A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.
- Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
- Preclinical Alzheimer's Disease: Definition, natural history, and diagnostic criteria.
Schools
Northwestern Center Feinberg School of Medicine
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Alzheimer's Disease
- Anterior Horn Disease
- Ataxia
- Brain Aneurysm
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Elected Member
Education
-
UCSF -
UCSF Medical Center -
Northwestern University Feinberg School of Medicine
Hospital
-
Barnes-Jewish Hospital
Drug Facts
| NPI NUMBER | 1972521789 | |
| NPPES Provider LastName | HOLTZMAN | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 631101026 | |
| NPPES Provider State | MO | |
| Specialty Description | Neurology | |
| Total Claim Count | 103.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1972521789 |
| Last Name Of The Provider | HOLTZMAN |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. B J. Snider, MD |
|
|
Andrew Findlay
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sean Goretzke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory F. Wu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Min Pan, MD |
|
|
Dr. Dante O. Garrido, MD |
|
|
Dr. Abhay Kumar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David B. Clifford, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth A. Strong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rafael Galindo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mitchell J. Hargis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jazba H. Soomro, MD
This Doctor is OpenDoctor Recommended.
|